Medical Oncologist
Dr. Minh Trương Công
Medical Oncologist | Oncology Researcher
Medical Oncologist specializing in thoracic and urogenital cancer treatments at Vietnam National Cancer Hospital (K Hospital). Dedicated to improving patient outcomes through evidence-based medicine and clinical research.
Research Interests
Thoracic Oncology
EGFR-mutant NSCLC, uncommon EGFR mutations, treatment optimization with afatinib, real-world evidence in lung cancer management.
Breast Oncology
HR+/HER2− metastatic breast cancer, CDK4/6 inhibitors combined with aromatase inhibitors, real-world effectiveness and safety.
Gynecologic Oncology
Cervical cancer treatment outcomes, concurrent chemoradiation, FIGO 2018 staging system, prognosis factors.
Real-World Evidence
Multicenter cohort studies evaluating treatment effectiveness and safety in Vietnamese patient populations; bridging clinical trial data to practice.
Education
Resident doctor of Oncology
Hanoi Medical University
September 2018 – August 2021
- Master's degree included in residency program
- Achieved a GPA of 8.7/10
General Practitioner
Hanoi Medical University
August 2012 – August 2018
- GPA: 8.1/10
Clinical Experience
Medical Oncologist
Vietnam National Cancer Hospital (K Hospital), Hanoi
- Specializing in Medical Oncology 2 department
- Focus on thoracic and urogenital cancer treatments
Publications
2025
Optimizing afatinib dosage: enhancing treatment outcomes and minimizing toxicities in advanced EGFR-mutated non-small cell lung cancer patients in Vietnam
Cam Phuong Pham, Hung Kien Do, Anh Tu Do, Tuan Khoi Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Van Luan Pham, Minh Hai Nguyen, Thi Thai Hoa Nguyen, Thi Bich Phuong Nguyen, Ha Thanh Vu, Thi Thuy Hang Nguyen, Van Thai Pham, Le Huy Trinh, Khac Dung Nguyen, Hoang Gia Nguyen, Cong Minh Truong, Tran Minh Chau Pham, Van Tai Nguyen
Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring epidermal growth factor receptor-G719X mutation treated by afatinib: real-world data from a multicenter study in Vietnam
Van Luan Pham, Cam Phuong Pham, Thi Thai Hoa Nguyen, Tuan Khoi Nguyen, Minh Hai Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Hung Kien Do, Ha Thanh Vu, Thi Thuy Hang Nguyen, Van Thai Pham, Le Huy Trinh, Hoang Gia Nguyen, Cong Minh Truong, Tran Minh Chau Pham, Thi Bich Phuong Nguyen
Real-World Evidence for First-Line afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X/L861Q/S768I
Thanh Ha Vu, Thi Hoa Thai Nguyen, To Van Ta, Minh Cong Truong, Thang Bui Xuan, Anh Tuan Nguyen, Cao Van Nguyen, Hang Thuy Thi Nguyen, Tuyet Thi Doan, Thanh Thi Vu, Dung Khac Dinh, Giang Vinh Le, Hung Huy Hoang, Chi Khanh Duong, Linh Khanh Dao
Real-World Effectiveness and Safety of Ribociclib Plus Aromatase Inhibitors in Patients with HR+/HER2- Metastatic Breast Cancer: A Multicenter Experience from Vietnam
Hoa Nguyen, Quang Le, Huyen Phung, Quang Nguyen, Huong Vu, Minh Truong
2024
Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam
Van Luan Pham, Tuan Anh Le, Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Minh Hai Nguyen, Thi Anh Thu Hoang, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi Thuy Hang Nguyen, Van Thai Pham, Le Huy Trinh, Khac Dung Nguyen, Hoang Gia Nguyen, Cong Minh Truong, Tran Minh Chau Pham, Thi Bich Phuong Nguyen
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Van Luan Pham, Minh Hai Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi Thuy Hang Nguyen, Van Thai Pham, Le Huy Trinh, Khac Dung Nguyen, Hoang Gia Nguyen, Cong Minh Truong, Tran Minh Chau Pham, Thi Bich Phuong Nguyen
2021
Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam
Thanh Vu, Hoa Nguyen, Linh Dao, Chi Duong, Cao Nguyen, Tuyet Doan, Hang Nguyen, Hung Hoang, Dung Dinh, Giang Le, Thanh Vu, Minh Truong, Long Nguyen
Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam
Huyen Phung, Minh Truong, Long Nguyen, Anh Dang, Thanh Vu, Hoa Nguyen
Achievements & Awards
International Clinical Research Scholars (ICRS) Program Award
ASCO Asia Pacific Regional Council
- Awarded by ASCO Asia Pacific Regional Council with support from ASCO Conquer Cancer Mission Endowment
- Recognizes professional achievements and potential as a leader of oncology research
- Participating in a 1-year program providing investigator training and mentorship from research experts
TLCS Research Investigator Award
ASPIRE Workshop, Taipei
- Recognized for presentation: 'A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam'
Contact
Address
Phone
Nationality
Languages